Author

Jiji Wang

Observed name: J. Wang

Institution: Hunan Cancer Hospital

Observed institution: Hunan Cancer Hospital

ORCID: 0009-0006-5833-0266

Observed ORCID: 0009-0006-5833-0266

OpenAlex ID: A5081733792

VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial

2022 · M.R. Mirza, X. Wu, et al. · Annals of Oncology · 10

37MO Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial

2023 · L. Pan, L. Wu, et al. · ESMO Open · 3

35O Overall survival of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer adjusted for subsequent PARPi use in placebo group: Results from an ad hoc interim analysis for the phase III NORA study

2023 · X. Wu, J. Zhu, et al. · ESMO Open · 1

Works count: 3

Citation count: 14

H-index: 2

I10-index: 1